Borui Kang

Title: Borui Kang: Innovator in Targeted Degradation of Bruton's Tyrosine Kinase

Introduction

Borui Kang is a notable inventor based in New Orleans, LA (US). He has made significant contributions to the field of pharmacology, particularly in the development of compounds aimed at treating proliferative diseases and autoimmune disorders.

Latest Patents

Kang holds a patent for "Substituted pyrimidines for the targeted degradation of Bruton's tyrosine kinase." This patent describes compounds that serve as degraders and inhibitors of Bruton's tyrosine kinase (BTK). The compounds are designed to bind to both BTK and E3 ubiquitin ligase (CRBN), facilitating the degradation of the target protein by the proteasome. The methods for synthesizing these compounds and their pharmacological activities are also detailed in the patent. The compounds have potential applications in treating hematological cancers and rheumatoid arthritis, including non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL).

Career Highlights

Throughout his career, Borui Kang has worked with various organizations, including Endotarget Inc. and Xavier University of Louisiana. His work has focused on innovative approaches to drug development and targeted therapies.

Collaborations

Kang has collaborated with notable colleagues such as Xianyou Peng and Guangdi Wang, contributing to advancements in his field.

Conclusion

Borui Kang's innovative work in the targeted degradation of Bruton's tyrosine kinase showcases his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of various diseases.